Roche für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 851311 / ISIN: CH0012032113

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Roche Holding AG (Inhaberaktie)

08.01.25		Roche purchases shares in tender offer for Poseida Therapeutics, Inc. (Roche Holding AG)
08.01.25		Roche purchases shares in tender offer for Poseida Therapeutics, Inc. (GlobeNewswire)
19.12.24		Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease (Roche Holding AG)
19.12.24		Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease (GlobeNewswire)
18.12.24		Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution (GlobeNewswire)
18.12.24		Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution (Roche Holding AG)
13.12.24		Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness (GlobeNewswire)
13.12.24		Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities (Roche Holding AG)
13.12.24		Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities (GlobeNewswire)
10.12.24		New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma (Roche Holding AG)
10.12.24		New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma (GlobeNewswire)
09.12.24		Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash (Roche Holding AG)
09.12.24		Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash (GlobeNewswire)
08.12.24		Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma (Roche Holding AG)
08.12.24		Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma (GlobeNewswire)
05.12.24		FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
05.12.24		FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
26.11.24		Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies (GlobeNewswire)
26.11.24		Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies (Roche Holding AG)
26.11.24		Roche reports update on Phase III SKYSCRAPER-01 study results (GlobeNewswire)
26.11.24		Roche reports update on Phase III SKYSCRAPER-01 study results (Roche Holding AG)
05.11.24		Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 (Roche Holding AG)
05.11.24		Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 (GlobeNewswire)
31.10.24		Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease (Roche Holding AG)
31.10.24		Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease (GlobeNewswire)
31.10.24		New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer (Roche Holding AG)
31.10.24		New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer (GlobeNewswire)
23.10.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months (Roche Holding AG)
23.10.24		[Ad hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von 9% (CER) auch im dritten Quartal 2024; Konzernverkäufe steigen in den ersten neun Monaten um 6% (GlobeNewswire)
23.10.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months (GlobeNewswire)
18.10.24		Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study (GlobeNewswire)
18.10.24		Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study (Roche Holding AG)
14.10.24		Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate (Roche Holding AG)
14.10.24		Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate (GlobeNewswire)
11.10.24		FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
11.10.24		FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (GlobeNewswire)
10.10.24		Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY (GlobeNewswire)
10.10.24		Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY (Roche Holding AG)
26.09.24		Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis (GlobeNewswire)
26.09.24		Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis (Roche Holding AG)
24.09.24		Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses (Roche Holding AG)
24.09.24		Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses (GlobeNewswire)
23.09.24		WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions (GlobeNewswire)
23.09.24		WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions (Roche Holding AG)
19.09.24		Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses (Roche Holding AG)
19.09.24		Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses (GlobeNewswire)
16.09.24		FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (GlobeNewswire)
16.09.24		FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (Roche Holding AG)
13.09.24		FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy (GlobeNewswire)
13.09.24		FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy (Roche Holding AG)

Zurück | 1 | 2 | Weiter

Newssuche

Roche Peer Group Nachrichten

25.04.25		Bayer-Aktie: Aktionäre üben auf HV scharfe Kritik - Kapitalerhöhung möglich
25.04.25		Springworks-Aktie mit kräftigem Plus: Merck stärkt Life-Science-Sparte mit geplanter SpringWorks-Übernahme - Merck-Aktie höher
25.04.25		Dow Jones 30 Industrial-Wert Johnson Johnson-Aktie: Über diese Dividende können sich Johnson Johnson-Aktionäre freuen
25.04.25		S&P 500-Wert Pfizer-Aktie: Über diese Dividendenzahlung können sich Pfizer-Aktionäre freuen
25.04.25		Buy von UBS AG für Merck-Aktie
25.04.25		Merck-Analyse: Overweight-Bewertung für Merck-Aktie von JP Morgan Chase & Co.
25.04.25		DAX 40-Papier Bayer-Aktie: So viel Verlust hätte eine Investition in Bayer von vor 5 Jahren bedeutet
24.04.25		EVOTEC-Aktie gewinnt: EVOTEC erhält Erfolgszahlungen von Bristol Myers Squibb

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	28.04.2025 05:50
Kaufwert:	EUR
	Hinzufügen Speichern

Roche Aktie

WKN: 851311 / ISIN: CH0012032113

Nachrichten zu Roche Holding AG (Inhaberaktie)

Newssuche

Roche Peer Group Nachrichten

Meistgelesene Nachrichten